Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Clinical trial NCT03777124 · TERMINATED

Trial details

NCT number: NCT03777124
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

NSCLC Stage IV KRAS Gene Mutation PD-1 Antibody Chemotherapy Effect

Start date: 2019-07-11
Primary completion: 2023-06-29
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.